Martić et al., 2015 - Google Patents
Transplanted tumor growth and the incidence of T-lymphocyte populations in the spleen of newcastle virus-treated miceMartić et al., 2015
View HTML- Document ID
- 16264899459057738744
- Author
- Martić A
- Ivanković S
- Antica M
- Hiršl N
- Jukić T
- Jurin M
- Publication year
- Publication venue
- Cancer Biotherapy and Radiopharmaceuticals
External Links
Snippet
C3Hf/HZgr mice were transplanted with SCCVII carcinoma cells and treated with Newcastle disease virus (NDV). The treatment slows down the growth of transplanted tumor. Furthermore, by using specific monoclonal antibodies, the frequencies of CD4+, CD8+, and …
- 210000001744 T-Lymphocytes 0 title abstract description 37
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yin et al. | Effect of low-dose radiation therapy on abscopal responses to hypofractionated radiation therapy and anti-PD1 in mice and patients with non-small cell lung cancer | |
| Vandenberk et al. | Exploiting the immunogenic potential of cancer cells for improved dendritic cell vaccines | |
| Kim et al. | The role of dendritic cells in tumor microenvironments and their uses as therapeutic targets | |
| Korbelik et al. | Photodynamic therapy-generated vaccines: relevance of tumour cell death expression | |
| Ishida et al. | Dendritic cells transduced with wild‐type p53 gene elicit potent anti‐tumour immune responses | |
| Wachowska et al. | 5-Aza-2′-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy | |
| Kravtsov et al. | Roles of CD4+ T cells as mediators of antitumor immunity | |
| Bersanelli et al. | Immunological insights on influenza infection and vaccination during immune checkpoint blockade in cancer patients | |
| CN109568570B (en) | Anti-tumor vaccine compound, preparation method, injection and application | |
| Reginato et al. | Photodynamic therapy downregulates the function of regulatory T cells in patients with esophageal squamous cell carcinoma | |
| CN103230600B (en) | Anti-hepatocarcinoma whole-cell vaccines that HBx modifies and its production and use | |
| Akutsu et al. | Combination of direct intratumoral administration of dendritic cells and irradiation induces strong systemic antitumor effect mediated by GRP94/gp96 against squamous cell carcinoma in mice | |
| Son et al. | Improvement of antitumor effect of intratumoral injection of immature dendritic cells into irradiated tumor by cyclophosphamide in mouse colon cancer model | |
| He et al. | CCL3 and CCL20-recruited dendritic cells modified by melanoma antigen gene-1 induce anti-tumor immunity against gastric cancer ex vivo and in vivo | |
| Mikysková et al. | Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF | |
| Simovic et al. | Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy | |
| Wang et al. | Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy | |
| Huang et al. | Anti-tumor efficacy of an adjuvant built-in nanovaccine based on ubiquitinated proteins from tumor cells | |
| Gardam et al. | Targeting the dendritic cell-T cell axis to develop effective immunotherapies for glioblastoma | |
| Xiao et al. | Effect of stereotactic radiotherapy on immune microenvironment of lung cancer | |
| Tiwari et al. | Immunotherapy: Advancing glioblastoma treatment—A narrative review of scientific studies | |
| Tatsuta et al. | Complete elimination of established neuroblastoma by synergistic action of γ-irradiation and DCs treated with rSeV expressing interferon-β gene | |
| Jain | Personalized cancer vaccines | |
| Nejad et al. | Antitumor immunity enhancement through Newcastle viral oncolysate in mice model: A promising method to treat tumors | |
| Martić et al. | Transplanted tumor growth and the incidence of T-lymphocyte populations in the spleen of newcastle virus-treated mice |